Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 19 views

    Local Literature

    Uploaded by

    Miyang
    Dengue cases in the Philippines have reached 146,062 so far in 2019, leading to 622 deaths, mostly among children under 10. This outbreak came after Sanofi Pasteur's dengue vaccine Dengvaxia was banned in 2018 due to dozens of child deaths linked to the vaccine. While Dengvaxia remains the only available dengue vaccine, the WHO only recommends it for those over 9 living in high-risk areas, as it can increase risks for those not previously exposed to dengue. The Dengvaxia scandal reduced immunization rates in the Philippines, resulting in measles and dengue epidemics. The government is working to control mosquitos and find alternatives to Dengvaxia

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Local Literature

    Uploaded by

    Miyang
    19 views2 pages
    Dengue cases in the Philippines have reached 146,062 so far in 2019, leading to 622 deaths, mostly among children under 10. This outbreak came after Sanofi Pasteur's dengue vaccine Dengvaxia was banned in 2018 due to dozens of child deaths linked to the vaccine. While Dengvaxia remains the only available dengue vaccine, the WHO only recommends it for those over 9 living in high-risk areas, as it can increase risks for those not previously exposed to dengue. The Dengvaxia scandal reduced immunization rates in the Philippines, resulting in measles and dengue epidemics. The government is working to control mosquitos and find alternatives to Dengvaxia

    Original Description:

    local lit

    Original Title

    local literature

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Dengue cases in the Philippines have reached 146,062 so far in 2019, leading to 622 deaths, mostly among children under 10. This outbreak came after Sanofi Pasteur's dengue vaccine Dengvaxia was banned in 2018 due to dozens of child deaths linked to the vaccine. While Dengvaxia remains the only available dengue vaccine, the WHO only recommends it for those over 9 living in high-risk areas, as it can increase risks for those not previously exposed to dengue. The Dengvaxia scandal reduced immunization rates in the Philippines, resulting in measles and dengue epidemics. The government is working to control mosquitos and find alternatives to Dengvaxia

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    19 views2 pages

    Local Literature

    Uploaded by

    Miyang
    Dengue cases in the Philippines have reached 146,062 so far in 2019, leading to 622 deaths, mostly among children under 10. This outbreak came after Sanofi Pasteur's dengue vaccine Dengvaxia was banned in 2018 due to dozens of child deaths linked to the vaccine. While Dengvaxia remains the only available dengue vaccine, the WHO only recommends it for those over 9 living in high-risk areas, as it can increase risks for those not previously exposed to dengue. The Dengvaxia scandal reduced immunization rates in the Philippines, resulting in measles and dengue epidemics. The government is working to control mosquitos and find alternatives to Dengvaxia

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 2

    Local Literature

    After causing hundreds of death this year, dengue has been considered a
    national epidemic that leads to the government banning the vaccine. According to the
    Department of Health, The country has recorded 146,062 cases of dengue from
    January through to 20 July this year, 98% more than the same period in 2018. The
    dengue outbreak has already taken the life of 622 people. Children with the age of 10
    and below are the ones who are severely affected by the disease. This outbreak led to
    the national ban on sale and distribution of the vaccine called Dengvaxia, a dengue
    vaccine made by French pharmaceutical firm Sanofi Pasteur, in February. The company
    has been the heart of the issue in the Philippines since 2017-2018, when dozens of
    children who were part of the national immunization died because they were injected by
    the vaccine. The firm confirmed that the vaccine could put the children at higher risk.

    As of now, Dengvaxia is the only dengue vaccination available to the public, but
    the World Health Organization suggests that the vaccine should only be given to
    children who are at high risk areas already exposed to the virus. According to Guardian
    News and Media Limited, that the vaccine is frequently used in mass immunization
    projects.

    After the government has adjourned the vaccination programs, they continued with
    investigations which led to the conclusion that Dengvaxia is the major cause of death of
    the patient. Sanofi Pasteur has shown “complete disregard of government rules and
    regulations” and in February the government decided to ban the vaccine.

    However, the nationwide fearfulness and wide-ranging misgiving of the


    vaccinations caused by Dengvaxia scandal led immunization rates for both dengue and
    measles to crash in the Philippines, resulting in an ongoing measles epidemic across the
    country and now a dengue epidemic. There are now 35 000 cases of measles, almost
    500 deaths, a 600% increase from last year.

    The Department of health was conducting a campaign to find and demolish


    mosquito breeding sites, while also publishing guidelines to make use of insect repellant
    and wear clothes that cover the skin. As stated by health minister Francisco Duque, “the
    government was finding ways to let Dengvaxia back into the Philippine market, but ruled
    out using the drug to combat the ongoing epidemic which has hit small children the
    hardest. “This vaccine does not squarely address the most vulnerable group which is the
    5-9 years of age,” Duque said. The vaccine, which is now licensed in 20 countries will be
    used for children age nine and above, according to the World Health Organization.

    Manila was also advised by the United Nations Agency that the vaccine was ”not
    recommended” as a solution to an outbreaks. It is also “ not cost effective with one dose
    costing one thousand pesos, said Duque.

    Other south-east Asian countries have also reported a surge in dengue cases this year,
    according to the UN’s World Health Organization. The organization said Malaysia had
    registered 62,421 cases through to 29 June, including 93 deaths, compared with 32,425
    cases with 53 deaths for the same period last year. Vietnam over the same period had
    81,132 cases with four deaths reported, compared with 26,201 cases including six deaths
    in 2018. In south Asia, Bangladesh has been facing its worst-ever dengue fever outbreak,
    putting a severe strain on the country’s already overwhelmed medical system.

    You might also like